

2021 MEDICARE

Inpatient Reimbursement Prospectus

Due to increasing financial risk to U.S. health care providers, physicians and hospitals have been centered on outcomes-based modifiers to Medicare payments for the last few years. We appreciate the role that Abbott procedures play in Medicare's reform programs and we believe that opportunities for success in a new era of reform continue to present themselves, such as treatment optimization, improving outcomes and avoiding downstream complications. Abbott believes that opportunities also exist from clinical to economic perspectives to impact patient care and hospital performance. We continue our mission to create relevant technology that improves meaningful patient outcomes, now made even more meaningful considering expanded financial risks posed to U.S. hospitals.

On September 2, 2020, the Centers for Medicare & Medicaid Services (CMS) released the FY 2021 Final Inpatient Prospective Payment System (IPPS) Rule, effective for inpatient services on October 1, 2020. Abbott has analyzed and summarized the varying impact to individual FY 2021 Medicare Severity-Diagnosis Related Group (MS-DRG) payments for procedures supported by our technologies or therapy solutions. Please refer to the full FY 2021 Final IPPS Rule to fully understand the changes to individual MS-DRGs.

Technology	MS- DRG	Description	Severity	FY 2020 - Correction Notice		FY 2021 - Final Rule				
				Payment	Discharges	Payment	Discharges	% Change (\$)	Change (Discharges)	
	216	Cardiac valve & other major cardiothoracic procedures with cardiac catheterization	MCC	\$62,855	6,176	\$67,039	5,603	6.7%	-573	
	217		CC	\$41,632	2,245	\$41,732	1,885	0.2%	-360	
	218		None	\$33,807	265	\$33,057	210	-2.2%	-55	
Surgical Valves	219	Cardiac valve & other	MCC	\$49,071	15,946	\$51,773	15,599	5.5%	-347	
	220	major cardiothoracic	CC	\$33,209	16,954	\$34,707	15,078	4.5%	-1,876	
	221	procedures without cardiac catheterization	None	\$28,767	2,677	\$29,259	2,419	1.7%	-258	
Septal Defects -	273		MCC	\$23,223	6,886	\$24,663	7,557	6.2%	671	
Atrial: PFO Closure; LAAC	274	Percutaneous intracardiac procedures	None	\$19,777	21,816	\$21,117	26,618	6.8%	4,802	
	228		MCC	\$39,346	4,153	\$39,948	4,437	1.5%	284	
Septal Defects - Ventricular	229	Other cardiothoracic procedures	CC None	\$25,692	4,907	\$25,633	5,252	-0.2%	345	
Endovascular	266	Endovascular Cardiac Valve Replacement & Supplement Procedure	MCC	\$44,573	18,384	\$45,617	20,765	2.3%	2,381	
Valve Replacement & Supplement - includes Aortic and Mitral	267		None	\$35,523	25,026	\$35,999	29,799	1.3%	4,773	
	231	Coronary bypass with PTCA	MCC	\$51,395	975	\$54,570	974	6.2%	-1	
	232		None	\$37,469	695	\$37,911	701	1.2%	6	
Coronary	233	Coronary bypass with cardiac catheterization	MCC	\$48,625	12,544	\$50,087	12,154	3.0%	-390	
Artery Bypas Graft (CABG)	234		None	\$32,586	14,849	\$34,177	13,951	4.9%	-898	
	235	Coronary bypass without cardiac catheterization	MCC	\$36,831	10,977	\$38,759	11,499	5.2%	522	
	236		None	\$25,218	19,641	\$26,229	19,732	4.0%	91	
	246	Percutaneous cardiovascular procedures with DES or 4+ stents	MCC	\$19,858	48,565	\$20,090	51,008	1.2%	2,443	
	247	Percutaneous cardiovascular procedure with DES	None	\$12,735	86,968	\$12,779	86,480	0.3%	-488	
Coronary (Stents)	248	Percutaneous cardiovascular procedures with BMS or 4+ stents	MCC	\$19,381	3,437	\$20,400	2,416	5.3%	-1,021	
	249	Percutaneous cardiovascular procedures with BMS	None	\$11,996	4,568	\$12,079	3,090	0.7%	-1,478	
	250	Perc cardiovasc proc w/o	MCC	\$15,961	4,177	\$16,215	4,435	1.6%	258	
	251	coronary artery stent	None	\$10,534	5,637	\$10,668	5,172	1.3%	-465	
Endovascular	252	Other vascular procedures	MCC	\$20,532	35,177	\$21,344	33,330	4.0%	-1,847	
	253		CC	\$16,315	26,085	\$17,056	23,996	4.5%	-2,089	
	254		None	\$11,392	11,899	\$11,630	10,545	2.1%	-1,354	
	270		MCC	\$31,985	18,560	\$33,304	18,960	4.1%	400	
Vascular Plugs	271	Other major cardiovascular services	CC	\$22,207	14,845	\$22,911	14,541	3.2%	-304	
	272		None	\$16,281	5,530	\$17,282	5,320	6.1%	-210	

Technology	MS- DRG	Description	Severity	FY 2020 - Correction Notice		FY 2021 - Final Rule				
				Payment	Discharges	Payment	Discharges	% Change (\$)	Change (Discharges)	
Carotid	034		MCC	\$23,494	1,132	\$25,546	1,372	8.7%	240	
	035	Carotid artery stent procedure	CC	\$14,409	3,052	\$15,021	3,672	4.2%	620	
	036	procedure	None	\$10,959	4,319	\$11,898	5,167	8.6%	848	
Percutaneous Heart Pump (PHP)	215	Other heart assist systems implant	None	\$80,654	6,845	\$71,716	7,744	-11.1%	899	
Renal	304	Ilymontoncion	MCC	\$6,832	15,492	\$7,042	16,720	3.1%	1,228	
Denervation	305	Hypertension	None	\$4,578	30,020	\$4,747	30,531	3.7%	511	
Leadless	228	Other cardiothoracic	MCC	\$39,346	4,153	\$39,948	4,437	1.5%	284	
Pacemaker	229	procedures	None	\$25,692	4,907	\$25,633	5,252	-0.2%	345	
	222	Cardiac defibrillator implant	MCC	\$52,229	1,836	\$54,126	1,867	3.6%	31	
	223	with cardiac catheterization with AMI/HF/shock	None	\$37,572	531	\$39,928	484	6.3%	-47	
	224	Cardiac defibrillator implant	MCC	\$46,293	2,213	\$47,320	2,335	2.2%	122	
Defibrillator Systems; CRT-D	225	with cardiac catheterization without AMI/HF/shock	None	\$35,356	1,650	\$36,166	1,634	2.3%	-16	
	226	Cardiac defibrillator	MCC	\$41,858	5,054	\$42,497	4,869	1.5%	-185	
	227	implant without cardiac catheterization	None	\$32,729	5,193	\$33,756	4,622	3.1%	-571	
Defibrillator	245	AICD generator procedures	NA	\$32,595	2,116	\$34,798	1,889	6.8%	-227	
Generator & Lead	265	AICD lead procedures	NA	\$19,536	657	\$21,613	580	10.6%	-77	
	242	Permanent cardiac pacemaker implant	MCC	\$23,228	19,033	\$23,926	18,961	3.0%	-72	
Pacemaker Systems; CRT-P	243		CC	\$15,831	26,105	\$16,278	25,229	2.8%	-876	
Systems, CK1-r	244		None	\$12,990	15,098	\$13,277	14,510	2.2%	-588	
Pacemaker	258	Cardiac pacemaker device replacement	MCC	\$19,144	664	\$20,576	547	7.5%	-117	
Generator	259		None	\$13,035	1,029	\$13,627	902	4.5%	-127	
	260	Cardiac pacemaker revision except device replacement	MCC	\$23,156	2,627	\$23,037	2,668	-0.5%	41	
Pacemaker Revision; ICMs	261		CC	\$12,196	3,594	\$12,799	3,653	4.9%	59	
Aevision; 101vi8	262		None	\$10,500	1,487	\$10,979	1,359	4.6%	-128	
	280	Acute myocardial infarction, discharged alive	MCC	\$10,208	87,710	\$10,452	91,216	2.4%	3,506	
	281		CC	\$6,063	48,941	\$5,991	48,347	-1.2%	-594	
Acute Myocardial	282	uischargeu anve	None	\$4,618	21,726	\$4,663	20,562	1.0%	-1,164	
Infarction	283		MCC	\$11,264	10,583	\$11,985	10,281	6.4%	-302	
(AMI)	284	Acute myocardial infarction, expired	CC	\$4,540	1,286	\$4,719	1,086	3.9%	-200	
	285		None	\$3,241	320	\$3,191	273	-1.5%	-47	
	308	Cardiac arrhythmia and conduction disorders	MCC	\$7,434	70,825	\$7,708	69,826	3.7%	-999	
Conduction	309		СС	\$4,734	89,056	\$4,817	86,595	1.8%	-2,461	
Disorders	310		None	\$3,501	59,439	\$3,589	55,723	2.5%	-3,716	
Catheter	273	Percutaneous intracardiac	MCC	\$23,223	6,886	\$24,663	7,557	6.2%	671	
Ablations	274	procedures	None	\$19,777	21,816	\$21,117	26,618	6.8%	4,802	


Technology	MS- DRG	Description	Severity	FY 2020 - Correction Notice		FY 2021- Final Rule				
				Payment	Discharges	Payment	Discharges	% Change (\$)	Change (Discharges)	
Left Ventricular Assist Device (LVAD)	001	Heart Transplant or Implant	MCC	\$172,959	2,409	\$186,171	2,213	7.6%	-196	
	002	of Heart Assist System	None	\$87,711	194	\$102,395	145	16.7%	-49	
	003	ECMO or Trach with MV >96 Hrs or PDX Exc Face, Mouth & Neck w/major.	NA	\$118,632	15,320	\$122,064	14,534	2.9%	-786	
Acute Mechanical	215	Other heart assist systems implant	NA	\$80,654	6,845	\$71,716	7,744	-11.1%	899	
Circulatory System (MCS)	870	Septicemia or Severe Sepsis with MV >96 hours or peripheral extracorporeal membrane oxygenation (ECMO)	NA	\$39,584	35,008	\$41,295	32,513	4.3%	-2,495	
CardioMEMS™ HF System	264	Other circulatory system operating room procedures	NA	\$20,267	10,829	\$20,875	10,418	3.0%	-411	
	025	Lead placement only, or lead	MCC	\$27,505	21,570	\$28,870	21,986	5.0%	416	
	026	revision OR System implant, single	CC	\$19,064	9,696	\$19,655	9,547	3.1%	-149	
	027	array generator plus leads	None	\$15,001	10,895	\$16,144	10,506	7.6%	-389	
Deep Brain	040	Generator only implant or replacement, single/multi array non-rechargeable or multi-array rechargeable	MCC	\$24,663	4,621	\$25,438	3,883	3.1%	-738	
Stimulation (DBS)	041		CC	\$14,843	6,645	\$15,110	6,428	1.8%	-217	
	042		None	\$11,568	2,385	\$12,115	2,414	4.7%	29	
	023	System implant, multi-array, rechargeable or non- rechargeable, plus leads	MCC	\$35,157	11,196	\$36,394	12,867	3.5%	1,671	
	024		None	\$25,139	4,251	\$25,276	4,624	0.5%	373	
	028	Whole System implantation or replacement(generator plus leads)	мсс	\$34,990	2,100	\$37,408	2,247	6.9%	147	
	029	Spinal procedures or spinal neurostimulators	CC	\$20,072	3,946	\$21,178	3,865	5.5%	-81	
	030	Spinal Procedures without CC/MCC	None	\$14,221	1,587	\$15,150	1,432	6.5%	-155	
	518	Back & neck procedures excluding spinal fusion, or disc device/neurostimulator	мсс	\$21,334	2,651	\$23,038	2,684	8.0%	33	
Spinal Cord Stimulation	519	Back and neck procedure except spinal fusion with CC	CC	\$11,946	8,673	\$12,583	8,454	5.3%	-219	
(SCS) for Pain	520	Back and neck procedure except spinal fusion without CC/MCC	None	\$8,374	7,732	\$9,110	6,513	8.8%	-1,219	
	040	Peripheral/Cranial Nerve	MCC	\$24,663	4,621	\$25,438	3,883	3.1%	-738	
	041	and Other Nervous System Procedures Generator implantation only or replacement (any type)	CC	\$14,843	6,645	\$15,110	6,428	1.8%	-217	
	042		None	\$11,568	2,385	\$12,115	2,414	4.7%	29	
	981		MCC	\$28,107	27,701	\$29,616	26,453	5.4%	-1,248	
	982	Extensive OR procedure unrelated to to principal Dx	CC	\$15,260	16,473	\$16,335	13,856	7.0%	-2,617	
	983		None	\$10,247	2,988	\$10,636	2,652	3.8%	-336	


Technology	MS- DRG	Description	Severity	FY 2020 - Correction Notice		FY 2021 - Final Rule				
				Payment	Discharges	Payment	Discharges	% Change (\$)	Change (Discharges)	
	163		MCC	\$30,504	11,581	\$31,877	10,876	4.5%	-705	
Major Chest	164	Major chest procedures	CC	\$15,845	15,985	\$16,941	15,822	6.9%	-163	
	165	-	None	\$11,574	8,299	\$12,267	8,222	6.0%	-77	
Aortic Heart	268	Aortic and Heart assist	MCC	\$42,452	3,697	\$44,700	3,661	5.3%	-36	
Assist	269	procedures except pulsation balloon	None	\$26,703	17,001	\$27,732	16,306	3.9%	-695	
Aortic Heart	286	Circulatory disorders except AMI, w card cath	MCC	\$13,753	43,136	\$14,231	44,705	3.5%	1,569	
Assist	287		None	\$7,212	60,364	\$7,392	57,260	2.5%	-3,104	
	299	Peripheral vascular disorders	MCC	\$9,074	17,958	\$9,843	19,593	8.5%	1,635	
Peripheral Vascular	300		CC	\$6,432	29,154	\$6,699	28,615	4.2%	-539	
vasculai	301		None	\$4,543	8,497	\$4,772	7,636	5.0%	-861	
Vascular: Other	673	Other kidney & urinary tract procedures	MCC	\$22,373	11,426	\$22,259	15,762	-0.5%	4,336	
Kidney and Urinary Tract	674		CC	\$15,298	6,710	\$15,300	7,325	0.0%	615	
	675		None	\$10,215	468	\$11,261	474	10.2%	6	
Heart Failure	291	Heart failure & shock	MCC	\$8,423	392,424	\$8,619	394,461	2.3%	2,037	
	292		CC	\$5,667	94,507	\$5,753	84,830	1.5%	-9,677	
	293		None	\$4,101	24,904	\$4,195	21,889	2.3%	-3,015	


MEDICARE PAYMENT RISK CONTINUES

As planned, Medicare will continue the scope and level of potential penalties of its payment reform initiatives, including the Hospital Readmissions Reduction Program and the Value-Based Purchasing Program. Risk to inpatient MS-DRG payments will continue at 3% and 2% respectively. The FY 2013 through FY 2021 makeup and impact of these two payment reform programs are illustrated in the charts on the next page. As payment reforms continue to impact healthcare management and as Medicare changes the way in which health care providers are paid, Abbott will continue to explore programs that seek to improve meaningful patient outcomes through shared risk.

For more information on how Medicare's rulemaking or reform initiatives may impact your facility or institution, please contact Abbott's Reimbursement team at 855-569-6430 or at AbbottEconomics@abbott.com.







DISCLAIMER

This document and the information contained herein is for general information purposes only and is not intended, and does not constitute, legal, reimbursement, business, clinical, or other advice. Furthermore, it is not intended to and does not constitute a representation or guarantee of reimbursement, payment, or charge, or that reimbursement or other payment will be received. It is not intended to increase or maximize payment by any payer. Similarly, nothing in this document should be viewed as instructions for selecting any particular code, and Abbott does not advocate or warrant the appropriateness of the use of any particular code. The ultimate responsibility for coding and obtaining payment/reimbursement remains with the customer. This includes the responsibility for accuracy and veracity of all coding and claims submitted to third-party payers. In addition, the customer should note that laws, regulations, and coverage policies are complex and are updated frequently, and, therefore, the customer should check with its local carriers or intermediaries often and should consult with legal counsel or a financial, coding, or reimbursement specialist for any questions related to coding, billing, reimbursement or any related issues. This material reproduces information for reference purposes only. It is not provided or authorized for marketing use.

REFERENCES

Hospital Inpatient Prospective Payment-Final Rule FY2021 Payment Rates. CMS-1735-F: https://www.cms.gov/medicare/acute-inpatient-pps/fy-2021-ipps-final-rule-home-page

Final Acute Inpatient Prospective Payment System FY 2020 Payment Rates. CMS-1716-F: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2020-IPPS-Final-Rule-Home-Page

Tables created by Abbott Health Economics and Reimbursement team based on analysis of Medicare 2021 IPPS Final rule as of September 2, 2020

- 1. CMS Readmissions Reduction Program (HRRP): https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program.html
- 2. CMS Hospital Value-Based Purchasing: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/ Hospital-Value-Based-Purchasing-.html
- 3. CMS Matrix of Key Dates: https://www.aha.org/hospital-acquired-condition-reduction-program/home

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular. com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Abbott

One St. Jude Medical Dr., St. Paul, MN 55117, USA, Tel: 1 651 756 2000 3200 Lakeside Dr., Santa Clara, CA 95054 USA, Tel: 1 800 227 9902

™ Indicates a trademark of the Abbott group of companies.

www.cardiovascular.abbott www.neuromodulation.abbott

Item approved for U.S. use only. HE&R, approved for non-promotional use only.

